Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China

Dawei Huang; Xiaoyuan Zhong; Yuxiong Jiang; Luyang Kong; Rui Ma; Jiajing Lu; Ying Li; Yuling Shi

doi:10.1093/bjd/ljae147

Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China

Br J Dermatol. 2024 Apr 18:ljae147. doi: 10.1093/bjd/ljae147. Online ahead of print.

Authors

Dawei Huang^{1

2}, Xiaoyuan Zhong^{1

2}, Yuxiong Jiang^{1

2}, Luyang Kong^{1

2}, Rui Ma^{1

2}, Jiajing Lu^{1

2}, Ying Li^{1

2}, Yuling Shi^{1

2}

Affiliations

¹ Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
² Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China.

PMID: 38634691
DOI: 10.1093/bjd/ljae147

Abstract

Background: Psoriasis and insulin resistance (IR) are closely related, but it remains unclear whether IR affects the treatment of patients with psoriasis.

Objective: The objective of this study was to investigate whether IR impairs the treatment response to biologic agents in patients with moderate-to-severe plaque psoriasis.

Methods: This project was based on a prospective cohort study design. Data for this study were collected from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), which is a prospective cohort exploring treatment strategies for psoriasis in China. IR was assessed using the triglyceride glucose-body mass index (TyG-BMI). Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA). Multiple logistic regression was used to explore the differences between patients with high and low levels of IR. Subgroup and sensitivity analyses were performed to examine the robustness of the study results.

Results: A total of 290 patients were included in the analysis. Based on the median TyG-BMI, the patients were divided into two groups: High and Low. The High group exhibited a higher prevalence of diabetes, higher BMI, fasting blood glucose, and triglyceride compared with the Low group. Further analysis of the treatment efficacy revealed that the High group had lower response rates for PASI 75, PASI 90, and PGA 0/1 after 12 weeks of treatment. In the Low group, 81.94% of patients achieved PASI 75, 58.33% achieved PASI 90, and 75.69% achieved PGA 0/1. However, the proportion of responses at each endpoint was significantly lower in the High group. The impairment in response to PGA 0/1 was more significant in the High group, indicated by lower odd ratios. Subsequent subgroup analysis and sensitivity analysis produced consistent results.

Conclusion: IR is associated with lower effectiveness of biologics in patients with psoriasis.

Clinical trial registration: [www.chictr.org.cn], identifier [ChiCTR2000036186].

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.